Quantifying CNS Transgene Expression with Precision and Context.
| Technical Question |
Franklin Biolabs Approach |
| What are the primary methods for quantifying AAV transgene expression in CNS tissue? |
We deploy a multi-platform strategy including qPCR and ddPCR for sensitive mRNA transcript quantification, Immunohistochemistry (IHC) and Immunofluorescence (IF) for protein localization within specific cell types, and ligand binding assays like ELISA or MSD for absolute protein quantification from tissue homogenates. |
| How do you ensure assay specificity for the transgene versus endogenous proteins? |
Specificity is established through rigorous validation protocols. This includes the design and verification of primer-probe sets for qPCR/ddPCR that do not amplify host genome sequences and the qualification of antibodies for IHC and ELISA using knockout tissue or cell lines to confirm target engagement without cross-reactivity. |
| What are the typical sample requirements for these CNS tissue analyses? |
Sample requirements are assay-dependent. Quantitative PCR and ligand binding assays typically utilize flash-frozen tissue to preserve nucleic acid and protein integrity. Histology requires precisely dissected, fixed (e.g., perfusion-fixed with PFA), and sectioned tissue to maintain anatomical context for cellular localization studies. |
| How does Franklin Biolabs address potential expression in non-target tissues like the DRG? |
We develop and validate bioanalytical methods with sufficient sensitivity to detect and quantify low-level transgene expression in relevant non-target tissues. This capability supports the evaluation of advanced vector designs, such as those incorporating microRNA target sites to de-target expression from specific cell populations and enhance the overall safety profile. |
Accurate quantification of transgene expression within the central nervous system (CNS) is fundamental to advancing AAV gene therapies. Determining the location, level, and duration of therapeutic protein expression directly informs dose-response relationships, confirms the mechanism of action, and is a key component of the safety assessment for an IND submission. Franklin Biolabs provides a suite of validated, GxP-compliant bioanalytical services designed to generate precise, reproducible data on transgene expression in complex CNS tissues.
A single analytical method is insufficient to capture the full dynamics of transgene expression in the CNS. A successful program requires an integrated approach that correlates data across multiple platforms to build a comprehensive biological narrative.
-
Nucleic Acid Quantification: We use quantitative PCR (qPCR) and droplet digital PCR (ddPCR) to measure AAV vector genome copies and transgene mRNA levels. These assays provide a direct measure of vector transduction and transcriptional activity within a specific CNS region.
-
Protein Localization: Our Histology core employs IHC and IF to visualize transgene protein expression at the cellular level. This anatomical context is vital for confirming that the therapeutic protein is present in the intended target cell population and absent from non-target cells.
-
Protein Quantification: For absolute measurement of protein levels, we develop and validate sensitive ligand binding assays (ELISA, MSD). These assays, run on tissue homogenates, provide the quantitative data needed to establish a clear link between dose, expression level, and therapeutic efficacy.
“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner
Evaluating non-target tissue biodistribution and expression is a primary objective of any IND-enabling toxicology program. As highlighted in recent research (PMID: 33177182), innovative vector engineering strategies can significantly improve safety profiles. The incorporation of specific microRNA target sequences into an AAV vector has been shown to selectively suppress transgene expression in sensitive tissues, such as the dorsal root ganglion (DRG), without impacting expression in the intended CNS targets.
Franklin Biolabs supports these advanced strategies by developing the highly sensitive bioanalytical assays required to verify that such de-targeting mechanisms are functioning as designed. Confirming the absence or reduction of expression in off-target sites provides powerful data supporting a favorable risk-benefit profile for your therapeutic candidate.
Our bioanalytical laboratories are part of a >100,000 sq ft facility designed for advanced preclinical ).
The data from these validated assays form a core component of the CMC and pharmacology/toxicology sections of an IND filing. Our rigorous GxP-compliant processes ensure that your transgene expression data is robust and submission-ready. This contributes to a projected 18-24 month IND timeline. Since 2019, programs supported by our scientific leadership have achieved a 100% IND success rate (the Franklin Biolabs brand launched in 2024).
